The aim of this study was to evaluate medical and pharmaceutical costs and health outcomes among commercially insured members treated for hepatitis C virus (HCV) infections from a large, academic institution.
Data are derived from the University of Texas System (UT SELECT) medical and pharmacy claims database. This study is a retrospective claims analysis of secondary, deidentified data from 2006 to 2016.
The number of HCV-infected and treated patients decreased from 22.5 per 10,000 members in 2006 to 0.15 per 10,000 members in 2016 (P < 0.0001). Medical and pharmacy paid per member per month (PMPM) costs were highest among HCV-infected members with advanced liver disease (total paid PMPM = $2737, medical PMPM = $1537, pharmacy PMPM = $1200).
The declining prevalence of acute HCV infections and the introduction of efficacious HCV treatment options for chronic HCV in this commercial population have resulted in significant reductions in HCV-related medical claims and the clinical sequelae of advanced liver diseases. Although HCV treatment to achieve sustained viral response remains expensive, the prevention of advanced liver disease decreased system-wide medical costs for this insured population.
Dell Medical School, The University of Texas at Austin, Austin, Texas; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland (Dr Leung and Dr Bernacki); University of the Incarnate Word School of Osteopathic Medicine, San Antonio, Texas (Mr Bernacki).
Address correspondence to: Nina Leung, PhD, MPH, Dell Medical School, The University of Texas at Austin, 1601 Trinity Street, Stop Z0200, Austin, TX 78712-1850 (Nina.Leung@austin.utexas.edu).
The authors report no conflicts of interest.
Clinical Significance: The declining incidence of acute HCV infections and the introduction of efficacious HCV treatment options for chronic HCV in this commercial population have resulted in significant reductions in HCV-related medical claims and the clinical sequelae of advanced liver diseases. Although HCV treatment to achieve sustained viral response (SVR) remains expensive, the prevention of advanced liver disease decreased system-wide medical costs for this insured population.
Supplemental digital contents are available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal's Web site (www.joem.org).
